Rob Mcewen, Chairman & Chief Owner, McEwen Mining Inc. & Dr. Michael Laflamme, Senior Scientist, Toronto General Hospital Research Institute.
Biography – Rob McEwen
Rob McEwen: Chairman and Chief Owner of McEwen Mining Inc., founder, former Chairman and CEO of GoldCorp Inc., that today is one of the world’s largest gold producers, by market
capitalization. During the last thirteen years as CEO, GoldCorp’s share price grew at a compound annual rate of 31%.
Rob and his wife have donated in excess of $50 million to encourage excellence and innovation
in healthcare and education. Their donations have funded the establishment of the McEwen
Centre for Regenerative Medicine, the McEwen Leadership Program at St. Andrew’s College,
McEwen School of Architecture at Laurentian University, Rob and Cheryl McEwen Graduate Study & Research Building Schulich School of Business, York University, in addition to Lakefield College, Margaret Cochenour Memorial Hospital and Red Lake Regional Heritage Centre.
Rob was awarded the Order of Canada in 2007. He holds an Honorary Doctor of Laws and MBA
from York University. Other awards include Mining Man of the Year, Most Innovative CEO and
most recently, Rob was inducted into the Canadian Mining Hall of Fame in 2017.
Rob is a member of the Dean’s Advisory Board, Schulich School of Business; X Prize Foundation: Board of Trustees; International Society of Stem Cell Research; Global Advisory Counsel; CEO,
Biography: Dr. Laflamme
Dr. Michael Laflamme is the Robert McEwen Chair in Cardiac Regenerative Medicine at University Health Network and a Senior Scientist in the Toronto General Hospital Research Institute. After obtaining an undergraduate degree in Physics at Georgetown University, Dr. Laflamme completed the Medical Scientist (MD/PhD) Training Program at Emory University, where he studied the regulation of calcium homeostasis by beta-adrenergic signaling in adult ventricular cardiomyocytes. After residency in Anatomic Pathology and subspecialty training in Cardiovascular Pathology at the University of Washington Medical Center, he completed a postdoctoral fellowship in the laboratory of Dr. Charles Murry, investigating the role of exogenous and endogenous stem cells in myocardial repair. His independent research career has been largely focused on the development of cell therapies based on human embryonic stem cells (hESCs), and his laboratory has made a number of important contributions in this area including 1) widely-used protocols to guide the differentiation of hESCs and induced pluripotent stem cells into cardiomyocytes or specialized cardiac subtypes (e.g. ventricular myocytes versus pacemaker cells), 2) the first proof-of-concept study showing that the transplantation of hESC-CMs can “remuscularize” scar tissue and improve left ventricular contractile function in rodent MI models, and 3) the first direct demonstration that grafts of hESC-CMs can electrically couple with host myocardium following transplantation in injured hearts. Dr. Laflamme has been the recipient of honors including the Society for Cardiovascular Pathology Young Investigator Award, the Perkins Coie Award for Discovery and the American Society of Gene & Cell Therapy Outstanding New Investigator Award. He is also a board-certified physician in Anatomic Pathology and practices diagnostic Cardiovascular Pathology.